Skip to main content
TipRanks
Go Ultimate75% OFF

Recce Pharmaceuticals Ltd. (R9Q) AI Stock Analysis

1 Followers
DE:R9Q

Recce Pharmaceuticals Ltd.

(Frankfurt:R9Q)

Rating:―N/A
Action:N/A
Date:―

No summary available

Positive Factors
Anti-infective pipelineThe pipeline is aimed at drug-resistant bacterial infections, an area of significant unmet medical need identified in the company description. If clinical development succeeds, these candidates could address important treatment gaps and provide a focused foundation for future commercial growth.
Negative Factors
Revenue collapseA fall to zero revenue, accompanied by negative gross profit, represents a major weakening in current commercial performance. Without a reliable revenue base, the company has limited internal funding capacity and remains highly dependent on successful development or future financing.

Recce Pharmaceuticals Ltd. (R9Q) vs. iShares MSCI Germany ETF (EWG)

-50%-25%0%25%50%75%100%125%DE:R9Q-2.83%EWG+1.23%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Market Cap
EUR 114.72M
Dividend Yield
―
Average Volume (3M)
―
Price to Earnings (P/E)
-7.2
Beta (1Y)
0.87
Revenue Growth
―
EPS Growth
45.78%
Country
Germany
Employees
8
Sector
Healthcare
Sector Strength
51
Industry
Biotechnology

Recce Pharmaceuticals Ltd. Business Overview & Revenue Model

Company Description

Recce Pharmaceuticals Ltd operates as a biotechnology enterprise, concentrating on the research, advancement, and market introduction of synthetic anti-infective treatments across Australia, the United States, and the United Kingdom. The company's fo...

Recce Pharmaceuticals Ltd. Peers Comparison

Overall Rating

UnderperformOutperform
Sector (51)

Financial Indicators

DE:R9Q against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
AU:BIOAU:BIO69NeutralAUD 79.84M19.8846.74%―29.68%1520.00%
Sector *51Neutral$7.86B-0.30-43.30%2.27%22.53%-2.21%
AU:IMCAU:IMC45NeutralAUD 11.95M-2.87-31.88%―5.85%45.13%
AU:BITAU:BIT43NeutralAUD 4.18M-3.56-54.03%――-100.00%
AU:SPLAU:SPL40UnderperformAUD 200.41M-24.56-42.35%―145.32%25.75%
AU:BOTAU:BOT38UnderperformAUD 27.63M-0.25-118.74%―499.47%31.20%

* Healthcare Sector Average

Performance Comparison

-50%0%50%100%DE:R9QAU:SPLAU:IMCAU:BOTAU:BIODec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
DE:R9Q and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
DE:R9QRecce Pharmaceuticals Ltd.0.21-0.00-1.90%
AU:BITBiotron Limited―――
AU:SPLStarpharma Holdings Limited0.420.0410.82%
AU:IMCImmuron Limited0.04-0.03-43.08%
AU:BOTBotanix Pharmaceuticals Limited0.01-0.11-91.30%
AU:BIOBiome Australia Ltd0.32-0.07-17.95%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.